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over 5% of adult vaccinees. Not only awareness that vac-
cine-induced immunity against HBV can wane over time,
but also awareness of which factors are associated with
waning immunity is important for preventing HBV infec-
tion in general and in the healthcare setting in particular.
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Towards a better liver allocation systemTo the Editor:
We read with great interest the Twelfth Forum on
Liver Transplantation published in Journal ofHepatology
[1]. Although we agree that theMELD score is basically a
‘‘justice system” which allocates patients according to
severity of liver disease however it is not necessarily the
best system [2] and indeed some limitations of theMELD
score were totally ignored in the forummentioned above.
For example, signiﬁcant variations of the MELD score
have been found using diﬀerent laboratory methodolo-
gies for INR measurement [3], as well as creatinine (Cr)
as we have published [4], and recently MELD-Na [5].
These variations, which may be cumulative when sum-
mated, lead to inequalities in prioritization of candidates,
especially in those with the highest priority for LT (more
jaundiced, greater renal dysfunction and lower serum so-
dium). A system of allocation that inherently does not
have standardized measurements cannot reﬂect true jus-
tice for individuals on waiting lists – this needs to be ad-
dressed. Moreover, there is an issue of potential gender
bias, highlighted by us [6] and reported by Moylan et al.
[7]. In the UNOS database, women were more likely to
die on the waiting list in the post-MELD era, compared
to the pre-MELD era, although women were listed with
lower median MELD scores, compared to men (14 vs.15, p < 0.001). These ﬁndings are likely to be the result
of not considering lower Cr in women for the same renal
function (GFR), as in men [8], as we documented in our
paper [6]. Interestingly, we found that correcting Cr by
equalising the GFR between men and women resulted
in an increase in MELD score by 2 or 3 points in 65%
of female LT candidates [6]. Our ﬁndings with Cr are also
pertinent to ethnicity diﬀerences. South Asian candidates
have worse GFR for the same Cr values than Caucasians,
and the opposite is true for black Africans, whether
Americans or otherwise. A correction factor for gender
and ethnicity could be introduced [6].
Regarding post-LT survival, it is true that the
MELD score is a weak predictor of mortality after
LT, so it cannot be used as a predictor. In order to as-
sess likelihood of a good outcome, we have proposed a
MELDD score – a second D for donor [2,8]. This
would allow a utilitarian approach to allocation on
top of the ‘‘solely justice approach” of MELD and
would lead to a transplant beneﬁt model for allocation.
A recent evaluation of the European Liver Transplant
Registry data [9], demonstrated that donor age, total
ischaemic time, and other operative and recipient fac-
tors, not included in MELD, signiﬁcantly and indepen-
dently impacted on outcomes post-LT with very good
Evangelos Cholongitas
Hepatobiliary Department, Royal Free Hospital,
London, UK
Giacomo Germani
Department of Surgical and Gastroenterological Sciences,
Gastroenterology, University of Padua, Padua, Italy
Emmanuel Tsochatzis
Hepatobiliary Department, Royal Free Hospital,
London, UK
Andrew K. Burroughs
Department of Surgery,
The Royal Free Sheila Sherlock Liver Centre,
Royal Free Hospital, London, UK
Liver Transplantation and Hepatobililary Medicine,
Royal Free Hospital, Pond Street,
Hampstead, London NW3 2QG, UK
Tel.: +44 20 74726229; fax: +44 20 74726226.
E-mail address: Andrew.Burroughs@royalfree.nhs.uk
doi:10.1016/j.jhep.2009.05.024
828 Letters to the Editor / Journal of Hepatology 51 (2009) 821–828calibration for 3- and 12-month mortality [9]. In addi-
tion, Ioannou G [10] has shown that several donor and
recipient characteristics are associated with post-LT
mortality. Interestingly, in this study [10], gender and
ethnicity in both donor and recipient were signiﬁcant
for predicting outcome after LT. We believe that dis-
ease-speciﬁc models (along with donor characteristics)
need to be developed, since recurrence of primary liver
disease aﬀects long-term post-LT survival [8]. Thus, we
agree with Schaubel et al. [1], who stated that a ‘‘trans-
plant beneﬁt” system is needed for allocation and pri-
oritization of recipients, taking into account donor
and/or operative factors and matching donor to recipi-
ent characteristics for optimal outcomes. ‘‘Matching”
has been shown to have a great impact on survival
beneﬁt from LT [11]. It is encouraging that a ‘‘trans-
plant survival beneﬁt” allocation system is currently
under consideration in the USA in order to maximize
lifetime gained through LT [12].
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